Form 4: CFO Robert Carter Boosts Stake in Oncology Institute

The Oncology Institute's CFO, Robert Ross Carter, acquired 195 shares of common stock through vested RSU awards.

Summary

• Robert Ross Carter, Chief Financial Officer of The Oncology Institute, Inc. (TOI), acquired 195 shares of common stock.
• The transaction occurred on November 17, 2025.
• The shares were acquired as Restricted Stock Unit (RSU) awards that fully vested upon grant, net of withholding tax obligations, with a transaction price of $0.00 per share.
• Following this transaction, Mr. Carter beneficially owns a total of 235,369 shares of The Oncology Institute, Inc. common stock.

Sentiment

Score: 6

Explanation: The acquisition of shares by a key executive, even a small amount, is generally viewed as a mildly positive signal of insider confidence in the company's performance and future outlook.

Positives

• An insider, the Chief Financial Officer, increased their beneficial ownership in the company, which can signal confidence in the company's future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This insider transaction reflects an individual executive's equity compensation and ownership changes, which is a routine aspect of corporate governance and executive compensation within the healthcare services industry.

Related Party Transactions

• The acquisition of 195 shares through RSU awards represents an equity compensation transaction between the company and its Chief Financial Officer, which is a common form of related party transaction.

Stakeholder Impact

• Shareholders may view the CFO's increased stake as a positive indicator of management's alignment with shareholder interests and confidence in the company's future.

Key Dates

Keywords

The Oncology Institute, TOI, Robert Carter, CFO, Insider Transaction, Form 4, Stock Acquisition, RSU, Equity Compensation